BiovelocITA is now completing its second round of capital raising, making a total of 14.6 million euro to be used in developing highly innovative medical research projects.
Banor SIM continues to support the Italian biotech accelerator and takes the contribution of primary private investors in BiovelocITA to 5.5 million euro.
Click here to read the press release: Banor, March 16, 2017.
The contents provided for in this section have not been audited by independent bodies. There’s no warranties, expressed or implied, regarding reliability, accuracy or completeness of the information and opinions contained. The informations are not based on assessment of the adequacy and do not consider the risk profile of the possible recipients, and therefore, should not be construed as personal recommendation and does not constitute investment advice, according to the Italian Legislative Decree n° 58/98. The contents of this site may not be reproduced or published whole or in part, for any purpose, or disclosed to third parties.